Key Dates

Related Announcements

• September 8, 2021 - High Priority HIV and Substance Use Research (R01 Clinical Trial Optional). See NOFO RFA-DA-22-040.

Issued by

National Institute on Drug Abuse (NIDA)

Purpose

The purpose of this Notice is to add additional application receipt date in 2024, to the list of application due dates, for RFA-DA-22-040, High Priority HIV and Substance Use Research (R01 Clinical Trial Optional).

Key Dates

Currently reads:

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

February 16, 2024

Modified to read (in Bold italics):

All applications are due by 5:00 PM local time of applicant organization.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date

August 02, 2024 

All other aspects of the NOFO remain the same.

Inquiries

Please direct all inquiries to:

Vasundhara Varthakavi, DVM, PhD
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-2146
Email: vasundhara.varthakavi@nih.gov

Richard A. Jenkins
National Institute on Drug Abuse (NIDA)
Telephone: 301-443-1923
Email: jenkinsri@nida.nih.gov

John Satterlee Ph.D.
National Institute on Drug Abuse (NIDA)
Telephone: 301-435-1020
Email: satterleej@nida.nih.gov

Raul N. Mandler, MD
National Institute on Drug Abuse (NIDA)
Telephone: 301-480-2541
Email: mandlerr@mail.nih.gov